Tìm theo
Imiglucerase
enzyme replacement agents
Thuốc Gốc
Biotech
CAS: 143003-46-7
ATC: A16AB02
ĐG : Genzyme Inc. , http://www.genzyme.ca
CTHH: C2532H3854N672O711S16
PTK: 55597.4000
Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C2532H3854N672O711S16
Phân tử khối
55597.4000
Độ kỵ nước
-0.168
Điểm đẳng điện tích
7.41
Dược Lực Học : Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of imiglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside leading to reduced anemia and thrombocytopenia, reduced spleen and liver size, and decreased cachexia
Cơ Chế Tác Dụng : Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.
Dược Động Học :

▧ Volume of Distribution :
* 0.09 to 0.15 L/kg
▧ Half Life :
3.6-10.4 min
▧ Clearance :
* 14.5 +/- 4.0 mL/min/kg
Chỉ Định : For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
Liều Lượng & Cách Dùng : Powder, for solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Genzyme
    Sản phẩm biệt dược : Cerezyme
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00053
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D02810
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/58468-4663-1
GenBank
http://www.ncbi.nlm.nih.gov/nuccore/M16328
PharmGKB
http://www.pharmgkb.org/drug/PA164742934
Wikipedia
http://en.wikipedia.org/wiki/Imiglucerase
RxList
http://www.rxlist.com/cgi/generic2/imiglucerase.htm
Drugs.com
http://www.drugs.com/cdi/imiglucerase.html
... loading
... loading